Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data

Chia Lang Hsu, Hsin Yi Chang, Jen Yun Chang, Wen Ming Hsu, Hsuan Cheng Huang, Hsueh Fen Juan

研究成果: 雜誌貢獻文章

13 引文 (Scopus)

摘要

MYCN, an oncogenic transcription factor of the Myc family, is a major driver of neuroblastoma tumorigenesis. Due to the difficulty in drugging MYCN directly, revealing the molecules in MYCN regulatory networks will help to identify effective therapeutic targets for neuroblastoma therapy. Here we perform ChIP-sequencing and small RNA-sequencing of neuroblastoma cells to determine the MYCN-binding sites and MYCN-associated microRNAs, and integrate various types of genomic data to construct MYCN regulatory networks. The overall analysis indicated that MYCN-regulated genes were involved in a wide range of biological processes and could be used as signatures to identify poor-prognosis MYCN-non-amplified patients. Analysis of the MYCN binding sites showed that MYCN principally served as an activator. Using a computational approach, we identified 32 MYCN co-regulators, and some of these findings are supported by previous studies. Moreover, we investigated the interplay between MYCN transcriptional and microRNA post-transcriptional regulations and identified several microRNAs, such as miR-124-3p and miR-93-5p, which may significantly contribute to neuroblastoma pathogenesis. We also found MYCN and its regulated microRNAs acted together to repress the tumor suppressor genes. This work provides a comprehensive view of MYCN regulations for exploring therapeutic targets in neuroblastoma, as well as insights into the mechanism of neuroblastoma tumorigenesis.
原文英語
頁(從 - 到)36293-36310
頁數18
期刊Oncotarget
7
發行號24
DOIs
出版狀態已發佈 - 一月 1 2016
對外發佈Yes

指紋

Genomics
Neuroblastoma
MicroRNAs
Carcinogenesis
Binding Sites
RNA Sequence Analysis
Biological Phenomena
Tumor Suppressor Genes
Transcription Factors
Therapeutics
Genes

ASJC Scopus subject areas

  • Oncology

引用此文

Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data. / Hsu, Chia Lang; Chang, Hsin Yi; Chang, Jen Yun; Hsu, Wen Ming; Huang, Hsuan Cheng; Juan, Hsueh Fen.

於: Oncotarget, 卷 7, 編號 24, 01.01.2016, p. 36293-36310.

研究成果: 雜誌貢獻文章

Hsu, Chia Lang ; Chang, Hsin Yi ; Chang, Jen Yun ; Hsu, Wen Ming ; Huang, Hsuan Cheng ; Juan, Hsueh Fen. / Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data. 於: Oncotarget. 2016 ; 卷 7, 編號 24. 頁 36293-36310.
@article{940e5099649b49aca1b8e6ef83170f26,
title = "Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data",
abstract = "MYCN, an oncogenic transcription factor of the Myc family, is a major driver of neuroblastoma tumorigenesis. Due to the difficulty in drugging MYCN directly, revealing the molecules in MYCN regulatory networks will help to identify effective therapeutic targets for neuroblastoma therapy. Here we perform ChIP-sequencing and small RNA-sequencing of neuroblastoma cells to determine the MYCN-binding sites and MYCN-associated microRNAs, and integrate various types of genomic data to construct MYCN regulatory networks. The overall analysis indicated that MYCN-regulated genes were involved in a wide range of biological processes and could be used as signatures to identify poor-prognosis MYCN-non-amplified patients. Analysis of the MYCN binding sites showed that MYCN principally served as an activator. Using a computational approach, we identified 32 MYCN co-regulators, and some of these findings are supported by previous studies. Moreover, we investigated the interplay between MYCN transcriptional and microRNA post-transcriptional regulations and identified several microRNAs, such as miR-124-3p and miR-93-5p, which may significantly contribute to neuroblastoma pathogenesis. We also found MYCN and its regulated microRNAs acted together to repress the tumor suppressor genes. This work provides a comprehensive view of MYCN regulations for exploring therapeutic targets in neuroblastoma, as well as insights into the mechanism of neuroblastoma tumorigenesis.",
keywords = "Genomics, MicroRNA, MYCN, Neuroblastoma, Regulatory network",
author = "Hsu, {Chia Lang} and Chang, {Hsin Yi} and Chang, {Jen Yun} and Hsu, {Wen Ming} and Huang, {Hsuan Cheng} and Juan, {Hsueh Fen}",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.9202",
language = "English",
volume = "7",
pages = "36293--36310",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "24",

}

TY - JOUR

T1 - Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data

AU - Hsu, Chia Lang

AU - Chang, Hsin Yi

AU - Chang, Jen Yun

AU - Hsu, Wen Ming

AU - Huang, Hsuan Cheng

AU - Juan, Hsueh Fen

PY - 2016/1/1

Y1 - 2016/1/1

N2 - MYCN, an oncogenic transcription factor of the Myc family, is a major driver of neuroblastoma tumorigenesis. Due to the difficulty in drugging MYCN directly, revealing the molecules in MYCN regulatory networks will help to identify effective therapeutic targets for neuroblastoma therapy. Here we perform ChIP-sequencing and small RNA-sequencing of neuroblastoma cells to determine the MYCN-binding sites and MYCN-associated microRNAs, and integrate various types of genomic data to construct MYCN regulatory networks. The overall analysis indicated that MYCN-regulated genes were involved in a wide range of biological processes and could be used as signatures to identify poor-prognosis MYCN-non-amplified patients. Analysis of the MYCN binding sites showed that MYCN principally served as an activator. Using a computational approach, we identified 32 MYCN co-regulators, and some of these findings are supported by previous studies. Moreover, we investigated the interplay between MYCN transcriptional and microRNA post-transcriptional regulations and identified several microRNAs, such as miR-124-3p and miR-93-5p, which may significantly contribute to neuroblastoma pathogenesis. We also found MYCN and its regulated microRNAs acted together to repress the tumor suppressor genes. This work provides a comprehensive view of MYCN regulations for exploring therapeutic targets in neuroblastoma, as well as insights into the mechanism of neuroblastoma tumorigenesis.

AB - MYCN, an oncogenic transcription factor of the Myc family, is a major driver of neuroblastoma tumorigenesis. Due to the difficulty in drugging MYCN directly, revealing the molecules in MYCN regulatory networks will help to identify effective therapeutic targets for neuroblastoma therapy. Here we perform ChIP-sequencing and small RNA-sequencing of neuroblastoma cells to determine the MYCN-binding sites and MYCN-associated microRNAs, and integrate various types of genomic data to construct MYCN regulatory networks. The overall analysis indicated that MYCN-regulated genes were involved in a wide range of biological processes and could be used as signatures to identify poor-prognosis MYCN-non-amplified patients. Analysis of the MYCN binding sites showed that MYCN principally served as an activator. Using a computational approach, we identified 32 MYCN co-regulators, and some of these findings are supported by previous studies. Moreover, we investigated the interplay between MYCN transcriptional and microRNA post-transcriptional regulations and identified several microRNAs, such as miR-124-3p and miR-93-5p, which may significantly contribute to neuroblastoma pathogenesis. We also found MYCN and its regulated microRNAs acted together to repress the tumor suppressor genes. This work provides a comprehensive view of MYCN regulations for exploring therapeutic targets in neuroblastoma, as well as insights into the mechanism of neuroblastoma tumorigenesis.

KW - Genomics

KW - MicroRNA

KW - MYCN

KW - Neuroblastoma

KW - Regulatory network

UR - http://www.scopus.com/inward/record.url?scp=84978081696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978081696&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9202

DO - 10.18632/oncotarget.9202

M3 - Article

C2 - 27167114

AN - SCOPUS:84978081696

VL - 7

SP - 36293

EP - 36310

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 24

ER -